Cargando…

Clinical considerations for the management of psoriasis in women [Image: see text] ()()

The burden of psoriasis is particularly high for women, who report lower levels of happiness (women: 18.5%; men: 11.3% lower vs. general population) and are more likely to experience stress (women: > 60%; men: 42%), loneliness (women: 25-28%; men: 19-24%), stigmatization (Feelings of Stigmatizati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice B., Ryan, Caitriona, Murase, Jenny E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637092/
https://www.ncbi.nlm.nih.gov/pubmed/31360745
http://dx.doi.org/10.1016/j.ijwd.2019.04.021
_version_ 1783436170640752640
author Gottlieb, Alice B.
Ryan, Caitriona
Murase, Jenny E.
author_facet Gottlieb, Alice B.
Ryan, Caitriona
Murase, Jenny E.
author_sort Gottlieb, Alice B.
collection PubMed
description The burden of psoriasis is particularly high for women, who report lower levels of happiness (women: 18.5%; men: 11.3% lower vs. general population) and are more likely to experience stress (women: > 60%; men: 42%), loneliness (women: 25-28%; men: 19-24%), stigmatization (Feelings of Stigmatization Questionnaire score; women: 93.2; men: 78.0), and reduced sexual activity (women: 33%; men: 19%) compared with men. The onset of psoriasis is bimodal, with one incidence peak (15-30 years) that coincides with the prime reproductive age for women, which poses specific challenges for their treatment. However, well-established guidelines for the treatment of women of childbearing age are lacking. Many women experience stabilization (21%) or improvement (55%) of their skin during pregnancy, but up to a quarter can experience disease worsening, and postpartum flares are common (> 50%). Therefore, balancing the risk of treatment with the risk of uncontrolled disease is important. Because half of pregnancies are unplanned, the implications of therapeutic options must be considered for all women with psoriasis who are sexually active, irrespective of intentions to start a family. Timely initiation of these discussions by health care professionals is paramount to prevent unintentional toxicity to the developing fetus. For example, acitretin, methotrexate, and oral psoralen/ultraviolet A are all contraindicated in pregnancy. Reassuringly, safety data for other psoriasis treatments during pregnancy are increasingly available, particularly for anti-tumor necrosis factor therapies. Despite encouraging data from pregnancy exposure registries and clinical studies now being included in anti-tumor necrosis factor drug labels, comfort with prescribing these therapies to pregnant women remains low (U.S. dermatologists: 21%; EU-5 dermatologists: 10%). In this article, we review issues specific to treating women of childbearing age with psoriasis and highlight the need for treatment guidelines to ensure consistent care and optimal outcomes for these patients.
format Online
Article
Text
id pubmed-6637092
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66370922019-07-29 Clinical considerations for the management of psoriasis in women [Image: see text] ()() Gottlieb, Alice B. Ryan, Caitriona Murase, Jenny E. Int J Womens Dermatol Article The burden of psoriasis is particularly high for women, who report lower levels of happiness (women: 18.5%; men: 11.3% lower vs. general population) and are more likely to experience stress (women: > 60%; men: 42%), loneliness (women: 25-28%; men: 19-24%), stigmatization (Feelings of Stigmatization Questionnaire score; women: 93.2; men: 78.0), and reduced sexual activity (women: 33%; men: 19%) compared with men. The onset of psoriasis is bimodal, with one incidence peak (15-30 years) that coincides with the prime reproductive age for women, which poses specific challenges for their treatment. However, well-established guidelines for the treatment of women of childbearing age are lacking. Many women experience stabilization (21%) or improvement (55%) of their skin during pregnancy, but up to a quarter can experience disease worsening, and postpartum flares are common (> 50%). Therefore, balancing the risk of treatment with the risk of uncontrolled disease is important. Because half of pregnancies are unplanned, the implications of therapeutic options must be considered for all women with psoriasis who are sexually active, irrespective of intentions to start a family. Timely initiation of these discussions by health care professionals is paramount to prevent unintentional toxicity to the developing fetus. For example, acitretin, methotrexate, and oral psoralen/ultraviolet A are all contraindicated in pregnancy. Reassuringly, safety data for other psoriasis treatments during pregnancy are increasingly available, particularly for anti-tumor necrosis factor therapies. Despite encouraging data from pregnancy exposure registries and clinical studies now being included in anti-tumor necrosis factor drug labels, comfort with prescribing these therapies to pregnant women remains low (U.S. dermatologists: 21%; EU-5 dermatologists: 10%). In this article, we review issues specific to treating women of childbearing age with psoriasis and highlight the need for treatment guidelines to ensure consistent care and optimal outcomes for these patients. Elsevier 2019-04-10 /pmc/articles/PMC6637092/ /pubmed/31360745 http://dx.doi.org/10.1016/j.ijwd.2019.04.021 Text en © 2019 Published by Elsevier Inc. on behalf of Women's Dermatologic Society. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Gottlieb, Alice B.
Ryan, Caitriona
Murase, Jenny E.
Clinical considerations for the management of psoriasis in women [Image: see text] ()()
title Clinical considerations for the management of psoriasis in women [Image: see text] ()()
title_full Clinical considerations for the management of psoriasis in women [Image: see text] ()()
title_fullStr Clinical considerations for the management of psoriasis in women [Image: see text] ()()
title_full_unstemmed Clinical considerations for the management of psoriasis in women [Image: see text] ()()
title_short Clinical considerations for the management of psoriasis in women [Image: see text] ()()
title_sort clinical considerations for the management of psoriasis in women [image: see text] ()()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637092/
https://www.ncbi.nlm.nih.gov/pubmed/31360745
http://dx.doi.org/10.1016/j.ijwd.2019.04.021
work_keys_str_mv AT gottliebaliceb clinicalconsiderationsforthemanagementofpsoriasisinwomenimageseetext
AT ryancaitriona clinicalconsiderationsforthemanagementofpsoriasisinwomenimageseetext
AT murasejennye clinicalconsiderationsforthemanagementofpsoriasisinwomenimageseetext